The Man Behind the Miracle Cure: Dr. Dennis Slamon's Fight Against Breast Cancer We weren’t able to create a summary for you. Refresh your page to try again. Dennis Joseph Slamon (born August 6, 1948), [1][2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab. Dennis Joseph Slamon (born August 6, 1948), [1][2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab. Feb 16, 2024 · UCLA Health oncologist Dr . Dennis Slamon and his team brought forward Herceptin, the first FDA-approved gene-based drug to fight cancer , back in 1988. Feb 16, 2024 · UCLA Health oncologist Dr . Dennis Slamon and his team brought forward Herceptin, the first FDA-approved gene-based drug to fight cancer , back in 1988. Dennis Joseph Slamon, is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breastcancer patients and the resulting treatment trastuzumab. DennisSlamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breastcancer, discussed the study's broad population and potential payer reactions. DennisSlamon and Donna Slamon attend the 20th Anniversary Taste for a Cure fundraiser benefitting UCLA's Jonsson Comprehensive Cancer Center at...
